in this issue
Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients
Aesica to Expand HPAPI Capacity at Two Sites in U.K.
8:07 AM MST | February 7, 2012 | Deepti Ramesh
Aesica Pharmaceuticals (Newcastle upon Tyne, U.K.), a provider of active pharma ingredients (API), formulations, and custom synthesis, says it plans to upgrade its API manufacturing facilities, enabling it to manufacture high potency APIs (HPAPIs) at commercial scale. The expansion will be carried out at Aesica’s facilities at Cramlington and Queenborough in the U.K., the company tells CW. The new HPAPI investment "will be staggered and will amount to about $6.6 million over the next three years. HPAPI capabilities are a definite priority for us at...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee